Multi-drug molecules comprising lestaurtinib, dinaciclib, and perifosine; axitinib, vinblastine, and celecoxib; and atiprimod, celastrol, and bortezomib were designed to target NTRK2, MYC, and AKT1; DDIT3, PDGFB, and JUN; and DDIT3, PDGFB, and JUN, to prevent HCC progression from stage I to II, II to III, and III to IV, respectively. Here, AKT1 is linked to hepatocellular carcinoma.